| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by investing activities | 22,208 | 17,155 |
| Proceeds from exercise of options and purchases from employee stock purchase plan | 28 | 13 |
| Net cash provided by financing activities | 28 | 13 |
| Net decrease in cash, cash equivalents and restricted cash | -5,690 | 2,114 |
| Cash and cash equivalents at beginning of period | 28,232 | - |
| Cash and cash equivalents at end of period | 22,542 | - |
Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics Inc. (OVID)